Survival from breast cancer in England and Wales up to 2001.

The standard post-operative treatment in most early trials was CMF polychemotherapy (cyclophosphamide, methotrexate, and 5-fluorouracil), but recent evidence suggests that there is a small but highly significant further survival benefit with anthracycline-based regimens (RR=0.89; 2 P <0.00001) ( EBCTCG, 2005 ), and these have become widely accepted as standard adjuvant chemotherapy.

also in 132,142 other papers